# Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

> **NCT01321723** · PHASE2 · COMPLETED · sponsor: **Unigene Laboratories Inc.** · enrollment: 97 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** PTH analog
- **DRUG:** Placebo
- **DRUG:** Forsteo (Teriparatide)

## Key facts

- **NCT ID:** NCT01321723
- **Lead sponsor:** Unigene Laboratories Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2013-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01321723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01321723, "Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01321723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*